Synovis Micro Companies Alliance, a subsidiary of Baxter International (BAX), has signed an exclusive multi-year deal with MediThinQ to distribute the SHIYA 3D surgical visualization platform globally, expanding Baxter’s footprint in digital surgical technology.
See our latest analysis for Baxter International.
The MediThinQ agreement arrives after a volatile stretch for Baxter International, with a 19.75% 90 day share price return contrasting with a 33.11% decline in 1 year total shareholder return, suggesting recent momentum is improving after a weak longer term experience.
If this move into digital surgery has your attention, it can be useful to widen the lens and see what other healthcare technology leaders are doing through the 40 healthcare AI stocks
With Baxter International shares down sharply over 1 year, yet up strongly over 90 days and trading below one estimate of intrinsic value, is this a reset that leaves upside on the table, or is the market already pricing in future growth?
Most Popular Narrative: 7.7% Undervalued
With Baxter International last closing at $19.89 against a widely followed fair value of $21.54, the leading narrative frames the stock as modestly undervalued and heavily focused on execution.
Ongoing portfolio optimization efforts, including divestitures, cost reductions, and a commitment to eliminate stranded costs by 2027, aim to streamline operations, improve efficiency, and drive net margin improvement, which should be reflected in future earnings growth.
Curious what has to change inside Baxter International for that fair value to stack up? The core story hinges on revenue shifts, margin rebuild, and a richer earnings mix. The exact hurdles and timelines behind those targets might surprise you.
Result: Fair Value of $21.54 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that Baxter International fair value story could be knocked off course if IV fluid usage stays structurally lower or if quality issues around infusion pumps drag on for longer.
Find out about the key risks to this Baxter International narrative.
Next Steps
With both risks and rewards in play for Baxter International, it helps to move quickly and pressure test the narrative against the numbers, starting with the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Baxter International?
If Baxter International has sharpened your focus on quality, now is the time to broaden your watchlist using focused stock ideas from the Simply Wall St Screener.
- Target resilience by reviewing companies in the 65 resilient stocks with low risk scores that score well on downside protection and stability.
- Hunt for value by scanning the 45 high quality undervalued stocks to see stocks where price and fundamentals may be out of sync.
- Spot potential early-stage opportunities by checking the 24 elite penny stocks with strong financials that combine smaller market caps with stronger financial profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com